SCHEMBL19973907

SCHEMBL19973907

O=C(N[C@H]1CCOc2c(C(=O)Nc3ccc(F)c(Cl)c3)ccc(F)c21)OCC1CCN(C(=O)O)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.40
CPT2 P23786 2/20 0.39
CPT1A P50416 2/20 0.39
CPT1B Q92523 2/20 0.39
CHRM3 P20309 7/20 0.39
LMNA P02545 4/20 0.38
MAPT P10636 3/20 0.38
CNR1 P21554 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
GPR35 Q9HC97 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
ENPP2 Q13822 1/20 0.37
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CHRM2 P08172 2/20 0.36
CHRM1 P11229 2/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19973909 1.00 IDO1 (0.40) IDO1CPT2CPT1ACPT1BCHRM3
SCHEMBL21189492 0.93 CHRM3 (0.40) IDO1CPT2CPT1ACPT1BCHRM3
SCHEMBL21189385 0.92 CHRM3 (0.38) IDO1CPT2CPT1ACPT1BCHRM3
SCHEMBL21189310 0.92 MAPT (0.40) IDO1CPT2CPT1ACPT1BCHRM3
SCHEMBL21189308 0.90 MAPT (0.49) LMNAMAPTCNR1NPSR1GPR35
SCHEMBL19973963 0.89 MCHR1 (0.40) CPT2CPT1ACPT1BCHRM3LMNA
SCHEMBL19973622 0.88 CHRM1 (0.47) CHRM3ALDH1A1SMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL19973889 0.88 CHRM1 (0.46) CHRM3ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL21189382 0.87 KMT2A (0.39) CPT2CPT1ACPT1BCHRM3LMNA
SCHEMBL21189537 0.84 MAPT (0.43) IDO1LMNAMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS IDO1 670/4885CPT2 2293/4885CPT1A 1280/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS IDO1 670/4885CPT2 2293/4885CPT1A 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.